

Synthesis of NHC Complexes by Oxidative Addition of 2-Chloro-N-methylbenzimidazole

Tim Kösterke, Tania Pape and F. Ekkehardt Hahn*

*Institut für Anorganische und Analytische Chemie, Westfälische Wilhelms-Universität
Münster, Corrensstrasse 30, D-48149 Münster, Germany*

Supporting Information

Description of Synthetic Procedures. All manipulations were performed under an argon atmosphere using standard Schlenk techniques or in a glove box. Glassware was oven dried at 130° C prior to use. Solvents were freshly distilled by standard procedures prior to use. ^1H , $^{13}\text{C}\{^1\text{H}\}$ and $^{31}\text{P}\{^1\text{H}\}$ NMR spectra were recorded on Bruker AVANCE I 400 or Bruker AVANCE III 400 spectrometers. Chemical shifts (δ) are expressed in ppm using the residual protonated solvent as an internal standard. Coupling constants are expressed in Hertz. Mass spectra were obtained with Orbitrap LTQ XL (Thermo Scientific) or Varian MAT 212 spectrometers. 2-Chlorobenzimidazole, $[\text{Pd}(\text{PPh}_3)_4]$ and $[\text{Pt}(\text{PPh}_3)_4]$ were purchased from commercial sources and used as received. Consistent microanalytical data for the metal complexes were difficult to obtain due to the large fluorine content (BF_4^- anions)

For assignment of NMR spectra see Figure 1.




Figure S1. Assignment of NMR resonances.

Synthesis of 2-Chloro-N-methylbenzimidazole 1. A sample of 2-chlorobenzimidazole (500 mg, 3.3 mmol) was dissolved in acetonitrile (10 mL).


Aqueous NaOH (5 mL of a 25 % solution) was added and the solution was cooled to 0 °C. Then, a solution of iodomethane (488 mg, 3.4 mmol, 0.22 mL) dissolved in acetonitrile (10 mL) was added slowly. The mixture was stirred for 3 d at ambient temperature. Subsequently, all solvents were removed *in vacuo* and the colorless residue was extracted three times with chloroform (20 mL each). The organic layer was dried with MgSO₄ and filtered. Removal of the solvent gave **1** as colorless solid. Yield: 0.478 g (2.87 mmol, 88%). ¹H NMR (400 MHz, CDCl₃): δ = 7.70–7.67 (m, 1H, H5), 7.30–7.25 (m, 3H, H6, H7, H8), 3.77 (s, 3H, NCH₃). ¹³C{¹H} NMR (100 MHz, CDCl₃): δ = 141.5 (C4), 140.9 (C2), 135.6 (C9), 123.1 (C7), 122.7 (C6), 119.3 (C5), 109.2 (C8), 30.5 (NCH₃). MS (EI, 20 eV): m/z (%) = 168 ([**1**]⁺ 30.2), 166 ([**1**]⁺ 100). Anal. Calcd (%): C, 57.67; H, 4.23; N, 16.81. Found: C, 57.47; H, 4.22; N, 16.90.

Synthesis of *trans*-[3]BF₄. Samples of 2-chloro-N-methylbenzimidazole **1** (4 mg, 0.026 mmol) and [Pd(PPh₃)₄] (30 mg, 0.026 mmol) together with an excess of NH₄BF₄ (0.1 mmol, 10 mg) were heated under reflux for 6 d in toluene (10 mL). After removal of the solvent *in vacuo* the residue was dissolved in dichloromethane and insoluble material was separated by filtration. The remaining solid was dried *in vacuo*. Colorless crystals of *trans*-[3]BF₄·CH₂Cl₂ were obtained by slow diffusion of diethyl ether into a saturated solution of *trans*-[3]BF₄ in dichloromethane. Yield: 17 mg (0.019 mmol, 73% of the solvent-free compound). ¹H NMR (400 MHz, DMSO-*d*₆/CDCl₃): δ = 12.84 (s, 1H, NH), 7.53–7.46 (m, 12H, Ph-H_{ortho}), 7.30 (t, ³J_{HH} = 7.4 Hz, 6H, Ph-H_{para}), 7.21 (t, ³J_{HH} = 7.4 Hz, 12H, Ph-H_{meta}), 7.08–7.02 (m, 2H, H6, H7), 6.93 (dd, ³J_{HH} = 6.1 Hz, ⁴J_{HH} = 2.6 Hz, 1H, H5), 6.79 (dd, ³J_{HH} = 6.3 Hz, ⁴J_{HH} = 2.3 Hz, 1H, H8), 3.31 (s, 3H, NCH₃). ¹³C{¹H} NMR (100 MHz, DMSO-*d*₆/CDCl₃): δ = 169.7 (t, ²J_{CP} = 9.2 Hz, C2), 133.6 (C4), 133.3 (t, ^{2/4}J_{CP} = 6.3 Hz, Ph-C_{ortho}), 133.0 (C9), 130.8 (Ph-C_{para}), 128.0 (t, ^{3/5}J_{CP} = 5.2 Hz, Ph-C_{meta}), 127.9 (t, ^{1/3}J_{CP} = 25.3 Hz, Ph-C_{ipso}), 122.9 (C6), 122.5 (C7), 110.9 (C5), 109.0 (C8), 33.6 (NCH₃). ³¹P{¹H} NMR (162 MHz, DMSO-*d*₆/CDCl₃): δ = 21.4 (s). HRMS (ESI, positive ions): m/z = 797.1234 (calcd for *trans*-[3]⁺ 797.1241).


Synthesis of the Mixture *cis*-[4]BF₄/*trans*-[4]BF₄. Samples of 2-chloro-N-methylbenzimidazole **1** (4 mg, 0.024 mmol) and [Pt(PPh₃)₄] (30 mg, 0.024 mmol) together with an excess of NH₄BF₄ (0.1 mmol, 10 mg) were heated under reflux for 6

d in toluene (10 mL). After removal of the solvent *in vacuo* the residue was dissolved in dichloromethane insoluble material was separated by filtration. Removal of the solvent gave a mixture of compounds *cis*-[4]BF₄/*trans*-[4]BF₄. The compounds could not be separated by chromatography. Slow diffusion of diethyl ether into a saturated dichloromethane solution of the mixture *cis*-[4]BF₄/*trans*-[4]BF₄ led to precipitation of colorless crystals. The two isomeric compounds (*cis*-[4](BF₄) thin plates and *trans*-[4](BF₄) needles) could be separated manually after crystallization. The *cis* isomer is the major component (95%) in the mixture with only a small amount of the *trans* isomer (5%) present. Both isomers of the mixture could be identified together in solution by different resonances in the ¹³C{¹H} and ³¹P{¹H} NMR spectra. Yield: 8 mg (0.008 mmol, 34% of the solvent-free mixture *cis*-[4]BF₄/*trans*-[4]BF₄). The NMR spectra are dominated by the resonances of the major compound *cis*-[4]BF₄ and only few resonances for the *trans* isomer could be identified in the ¹³C{¹H} NMR spectrum. ¹H NMR (400 MHz, DMSO-*d*₆/CDCl₃): δ = 12.98 (s, 1H, NH), 7.50–7.39 (m, 15H, Ph-H), 7.33 (d, ³J_{HH} = 5.3 Hz, 1H, H8), 7.29–7.23 (m, 12H, H5, H6, H7 and Ph-H), 7.15 (t, ³J_{HH} = 6.5 Hz, 6H, PPh₃-H_{meta} *trans* to NHC), 4.00 (s, 3H, NCH₃). ¹³C NMR (100 MHz, DMSO-*d*₆/CDCl₃, *cis* isomer): δ = 170.7 (dd, ²J_{CP(cis)} = 10.3 Hz, ²J_{CP(trans)} = 142.4 Hz, C2), 134.6 (PPh₃-C_{ortho} *trans* to NHC), 133.3 (PPh₃-C_{ortho} *cis* to NHC), 133.0 (C4 and C9), 131.6 (PPh₃-C_{para} *cis* to NHC), 130.9 (PPh₃-C_{para} *trans* to NHC), 128.7 (PPh₃-C_{ipso} *trans* to NHC), 128.4 (PPh₃-C_{meta} *cis* to NHC), 128.2 (PPh₃-C_{meta} *trans* to NHC), 127.5 (PPh₃-C_{ipso} *cis* to NHC), 123.6 (C6), 123.2 (C7), 111.8 (C5), 110.5 (C8), 34.0 (NCH₃). Resonances for the *trans* isomer: δ = 166.9 (C2), 133.3 (PPh₃-C_{ortho}), 133.0 (C4 and C9), 131.6 (PPh₃-C_{para}), 128.4 (PPh₃-C_{meta}), 127.5 (PPh₃-C_{ipso}), 123.6 (C6), 123.2 (C7), 111.8 (C5), 110.5 (C8), 34.0 (NCH₃). ³¹P{¹H} NMR (162 MHz, DMSO-*d*₆/CDCl₃): δ = 15.7 (d, Pt satellites, ¹J_{PtP} = 2223 Hz, ²J_{PP} = 19.2 Hz, PPh₃ *trans* to NHC, *cis* isomer), 11.1 (d, Pt satellites, ¹J_{PtP} = 3702 Hz, ²J_{PP} = 19.2 Hz, PPh₃ *cis* to NHC, *cis* isomer), 18.2 (s, Pt satellites, ¹J_{PtP} = 2524 Hz, *trans* isomer). HRMS (ESI, positive ions): *m/z* = 887.1823 (calcd for [*cis/trans*-[4]–BF₄]⁺ 887.1845).

Synthesis of [5].



Samples of 2-chloro-N-picolylbenzimidazole (5.9 mg, 0.024 mmol) and $[\text{Pt}(\text{PPh}_3)_4]$ (30 mg, 0.024 mmol) were heated under reflux for 6 d in tetrahydrofuran (10 mL). After removal of the solvent *in vacuo* the residue was dissolved in dichloromethane and insoluble material was separated by filtration. The remaining solid was dried *in vacuo*. Colorless crystals of the dinuclear complex $[\mathbf{5}] \cdot \text{H}_2\text{O} \cdot 0.5\text{Et}_2\text{O}$ were obtained by slow diffusion of diethyl ether into a saturated solution of $[\mathbf{5}]$ in dichloromethane. Yield: 7 mg (0.010 mmol, 42% of the solvent-free compound). ^1H NMR (400 MHz, CDCl_3): δ = 8.23 (d, $^3J_{\text{HH}}$ = 5.1 Hz, 2H, pyridine- H_ϵ), 7.90 (dd, $^3J_{\text{HP}}$ = 11.8 Hz, $^3J_{\text{HH}}$ = 7.4 Hz, 12H, PPh- H_{ortho}), 7.78 (d, $^3J_{\text{HH}}$ = 8.2 Hz, 2H, Ar-H), 7.28 (dt, $^3J_{\text{HH}}$ = 7.4 Hz, $^5J_{\text{HP}}$ = 3.6 Hz, 6H, PPh- H_{para}), 7.19 (td, $^3J_{\text{HH}}$ = 7.4 Hz, $^4J_{\text{HP}}$ = 2.4 Hz, 12H, PPh- H_{meta}), 6.93 (t, $^3J_{\text{HH}}$ = 8.2 Hz, 2H, Ar-H), 6.76 (t, $^3J_{\text{HH}}$ = 8.2 Hz, 2H, Ar-H), 6.71 (dd, $^3J_{\text{HH}}$ = 7.8 Hz, $^3J_{\text{HH}}$ = 5.1 Hz, 2H, pyridine- H_δ), 6.56 (d, $^3J_{\text{HH}}$ = 8.2 Hz, 2H, Ar-H), 6.03 (dd, $^3J_{\text{HH}}$ = 7.8 Hz, $^4J_{\text{HH}}$ = 1.8 Hz, 2H, pyridine- H_γ), 5.64 (d, $^3J_{\text{HH}}$ = 7.8 Hz, 2H, pyridine- H_β), 5.52 (d, $^2J_{\text{HH}}$ = 16.2 Hz, 2H, NCHH), 4.15 (d, $^2J_{\text{HH}}$ = 16.2 Hz, 2H, NCHH). $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, CDCl_3): δ = 159.8 (d, $^2J_{\text{CP}}$ = 8.8 Hz, NCN), 156.5 (pyridine- C_α), 148.6 (pyridine- C_ϵ), 141.5 (Ar-C), 136.3 (pyridine- C_γ), 134.6 (d, $^2J_{\text{CP}}$ = 10.7 Hz, PPh- C_{ortho}), 134.0 (Ar-C), 130.6 (d, $^4J_{\text{CP}}$ = 2.4 Hz, PPh- C_{para}), 130.0 (d, $^1J_{\text{CP}}$ = 61.6 Hz, PPh- C_{ipso}), 128.3 (d, $^2J_{\text{CP}}$ = 11.0 Hz, PPh- C_{meta}), 122.0 (pyridine- C_δ), 121.3 (Ar-C), 120.6 (Ar-C), 119.9 (pyridine- C_β), 116.5 (Ar-C), 109.3 (Ar-C), 51.5 (NCH_2). $^{31}\text{P}\{^1\text{H}\}$ NMR (162 MHz, CDCl_3): δ = 5.45 (s, Pt satellites, $^1J_{\text{PPt}}$ = 1814 Hz). HRMS (ESI, positive ions): m/z = 1402.2331 (30%, calcd for $[\mathbf{5}]$ 1402.2314), 1424.2128 (100%, calcd for $[\mathbf{5} + \text{Na}^+]$ 1424.2131).



Alkylation of *trans*-[3]BF₄ to *trans*-[6]X. To a solution of *trans*-[3]BF₄ (5 mg, 0.006 mmol) in dichloromethane (5 mL) was added KO^tBu (0.7 mg, 0.006 mmol) and MeOTf (0.8 mg, 0.006 mmol). The reaction mixture was stirred for 2 h. The solvent was removed *in vacuo* and the residue was washed with diethylether giving *trans*-[5]BF₄ as a yellow solid. HRMS (ESI, positive ions): $m/z = 811.1423$ (calcd for [[5]–BF₄]⁺ 811.1394). Consistent microanalytical data for *trans*-[5]X could not be obtained due to the possible presence of two different anions (BF₄[–] and OTf[–]).

X-ray Crystallography. Diffraction data were collected at $T = 153(2)$ K (*trans*-[3]BF₄·CH₂Cl₂, *cis*-[4]BF₄ and [5]·H₂O·0.5Et₂O) and at $T = 223(2)$ K (*trans*-[4]BF₄·0.5CH₂Cl₂) with a Bruker AXS APEX CCD diffractometer equipped with a rotation anode using graphite-monochromated Mo-K α radiation ($\lambda = 0.71073$ Å). Diffraction data were collected over the full sphere and were corrected for absorption. Structure solutions were found with the SHELXS-97¹ package using direct methods and were refined with SHELXL-97¹ against $|F^2|$ using first isotropic and later anisotropic thermal parameters (for exceptions see description of the individual molecular structures). Hydrogen atoms were added to the structure models in calculated positions.

***Trans*-[3](BF₄)·CH₂Cl₂.** Crystals suitable for an X-ray diffraction study were obtained by diffusion of diethyl ether into a saturated dichloromethane solution of [3](BF₄). C₄₅H₄₀N₂BCl₃F₄P₂Pd, $M = 970.29$, colorless crystal, $0.21 \times 0.06 \times 0.02$ mm³, monoclinic, space group $P2_1/c$, $Z = 4$, $a = 12.7079(4)$, $b = 10.4589(4)$, $c = 33.0698(12)$ Å, $\beta = 94.4330(10)^\circ$, $V = 4382.2(3)$ Å³, $\rho_{\text{calc}} = 1.471$ g·cm^{–3}, $\mu = 0.731$ mm^{–1}, ω - and ϕ -scans, 51827 measured intensities ($2.5^\circ \leq 2\theta \leq 61.0^\circ$), MoK α radiation, $\lambda = 0.71073$ Å, semiempirical absorption correction ($0.862 \leq T \leq 0.986$), 13321 independent ($R_{\text{int}} = 0.0405$) and 10283 observed intensities ($I \geq 2\sigma(I)$), refinement of 534 parameters against $|F^2|$ of all measured intensities with hydrogen atoms on calculated positions. $R = 0.0487$, $wR = 0.1272$, $R_{\text{all}} = 0.0672$, $wR_{\text{all}} = 0.1398$. The asymmetric unit contains one formula unit.

***Trans*-[4]BF₄·0.5CH₂Cl₂ and *cis*-[4]BF₄.** Crystals of both compounds, suitable for X-ray diffraction studies, precipitated simultaneously by slow diffusion of diethyl ether into a saturated dichloromethane solution of a mixture of *trans*-[4]BF₄/*cis*-[4]BF₄. Compound *trans*-[4](BF₄)·0.5CH₂Cl₂ crystallized as needles while crystals of *cis*-

[4](BF₄) crystallized as prisms.

Trans-[4]BF₄·0.5CH₂Cl₂: C_{44.50}H₃₉N₂BCl₂F₄P₂Pt, *M* = 1016.52, colorless crystal, 0.15 × 0.03 × 0.03 mm³, monoclinic, space group *P*2₁/*c*, *Z* = 4, *a* = 12.7733(6), *b* = 10.5578(5), *c* = 33.0376(15) Å, *β* = 94.4420(10)°, *V* = 4442.0(4) Å³, *ρ*_{calc} = 1.520 g·cm⁻³, *μ* = 3.401 mm⁻¹, *ω*- and *φ*-scans, 50985 measured intensities (3.2° ≤ 2*θ* ≤ 60.2°), MoK α radiation, *λ* = 0.71073 Å, semiempirical absorption correction (0.629 ≤ *T* ≤ 0.905), 12992 independent (*R*_{int} = 0.0397) and 9929 observed intensities (*I* ≥ 2σ(*I*)), refinement of 514 parameters against |*F*²| of all measured intensities with hydrogen atoms on calculated positions. *R* = 0.0445, *wR* = 0.1243, *R*_{all} = 0.0638, *wR*_{all} = 0.1350. The asymmetric unit contains one formula unit.

Cis-[4]BF₄: C₄₄H₃₈N₂BClF₄P₂Pt, *M* = 974.05, colorless crystal, 0.13 × 0.08 × 0.07 mm³, triclinic, space group *P*1̄, *Z* = 2, *a* = 10.4079(3), *b* = 12.9817(4), *c* = 16.6774(10) Å, *α* = 102.085(1)°, *β* = 104.508(1)°, *γ* = 106.140(1)°, *V* = 1998.97(10) Å³, *ρ*_{calc} = 1.618 g·cm⁻³, *μ* = 3.710 mm⁻¹, *ω*- and *φ*-scans, 23672 measured intensities (3.4° ≤ 2*θ* ≤ 60.0°), MoK α radiation, *λ* = 0.71073 Å, semiempirical absorption correction (0.644 ≤ *T* ≤ 0.781), 11585 independent (*R*_{int} = 0.0146) and 10834 observed intensities (*I* ≥ 2σ(*I*)), refinement of 497 parameters against |*F*²| of all measured intensities with hydrogen atoms on calculated positions. *R* = 0.0244, *wR* = 0.0619, *R*_{all} = 0.0268, *wR*_{all} = 0.0629. The asymmetric unit contains one formula unit.

[5]·H₂O·0.5Et₂O: C₆₄H₅₆N₆Cl₂O_{1.5}P₂Pt, *M* = 1456.17, colorless crystal, 0.18 × 0.06 × 0.02 mm³, monoclinic, space group *P*2₁/*c*, *Z* = 4, *a* = 20.6422(7), *b* = 12.4704(4), *c* = 24.1515(8) Å, *β* = 106.3130(10)°, *V* = 5966.7(3) Å³, *ρ*_{calc} = 1.621 g·cm⁻³, *μ* = 4.875 mm⁻¹, *ω*- and *φ*-scans, 57985 measured intensities (2.1° ≤ 2*θ* ≤ 60.0°), MoK α radiation, *λ* = 0.71073 Å, semiempirical absorption correction (0.474 ≤ *T* ≤ 0.909), 17351 independent (*R*_{int} = 0.0453) and 13450 observed intensities (*I* ≥ 2σ(*I*)), refinement of 725 parameters against |*F*²| of all measured intensities with hydrogen atoms on calculated positions. *R* = 0.0348, *wR* = 0.0867, *R*_{all} = 0.0544, *wR*_{all} = 0.0974. The asymmetric unit contains one formula unit. The water molecule is disordered over two position.

References

(1) *SHELXS-97*, *SHELXL-97*, G. M. Sheldrick, *Acta Crystallogr., Sect. A* **2008**, *64*, 112–122.